Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis.

Source: Kidney International - September 19, 2018 Category: Urology & Nephrology Authors: Michel Jadoul, Marina C. Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram L. Kasiske, Ching-Lung Lai, Jos é M. Morales, Priti R. Patel, Stanislas Pol, Marcelo O. Silva, Ethan M. Balk, Craig E. Gordon, Amy Ear Tags: Guideline Summary Source Type: research